Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Hypoxemic pneumonia is a major cause of hospitalization in Pulmonology. The patient's dependency on oxygen prevents early discharge from the hospital. An automated oxygen therapy is a system that allows administration of oxygen with a flow that is automatically adjusted to the patient's saturation, which is continuously monitored. This system has proven to be particularly effective with chronic obstructive pulmonary disease (COPD) patients, by decreasing the time spent in hypoxia and hyperoxia, and by accelerating the weaning of oxygen. Our hypothesis is that automated oxygen therapy leads to a diminution on the length of hospital stay.
Full description
Prolonged hospitalization has many consequences, including loss of autonomy and nosocomial infection. Moreover, these complications themselves lead to an extension of the length of stay. This has an impact on the cost of care: several studies have shown that hospitalization is the most costly factor in the management of pneumonia, and that even a small amount of hospital stay, led to significant financial savings. Automated oxygen therapy is a device that automatically adjusts with the saturation the amount of oxygen administered. Investigator hypothesis is that automated oxygen therapy could shorten the length of stay of patients hospitalized for hypoxemic pneumonia. One group of patients will receive the automated oxygen therapy and the other group will receive the standard Oxygen therapy. The investigator will compare in each group the average length of stay, the duration of oxygen therapy, the time spent outside of the target saturation, the cost on the medical-economic level and the patient's experience.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Adult
Patient living at home or in an institution
Patient hospitalized for less than 48 hours
Pneumonia defined (according to the 2006 French-speaking infectious pneumology society (SPILF) criteria) by:
Hypoxia : SpO2 < 94% in ambient air and/or PaO2< 60 mmHg in ambient air
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
128 participants in 2 patient groups
Loading...
Central trial contact
Elise Noel-Savina, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal